MPM
UTHR icon

Meritage Portfolio Management’s United Therapeutics UTHR Stock Holding History

Meritage Portfolio Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$375K Sell
769
-172
-18% -$80.1K 0.02% 251
2025
Q3 		$394K Sell
941
-532
-36% -$179K 0.03% 254
2025
Q2 		$423K Sell
1,473
-57
-4% -$17K 0.03% 262
2025
Q1 		$472K Buy
1,530
+84
+6% +$28.8K 0.03% 247
2024
Q4 		$510K Buy
1,446
+157
+12% +$57.7K 0.03% 244
2024
Q3 		$462K Buy
1,289
+113
+10% +$38.2K 0.03% 263
2024
Q2 		$375K Sell
1,176
-1
-0.1% -$265 0.02% 266
2024
Q1 		$270K Sell
1,177
-69
-6% -$15.6K 0.02% 307
2023
Q4 		$274K Buy
1,246
+21
+2% +$4.84K 0.02% 308
2023
Q3 		$277K Sell
1,225
-41
-3% -$9.44K 0.02% 295
2023
Q2 		$279K Buy
1,266
+207
+20% +$45.9K 0.02% 303
2023
Q1 		$237K Sell
1,059
-36
-3% -$8.88K 0.02% 285
2022
Q4 		$305K Buy
1,095
+37
+3% +$9.34K 0.02% 255
2022
Q3 		$222K Buy
1,058
+6
+0.6% +$1.34K 0.02% 276
2022
Q2 		$248K Buy
+1,052
New +$214K 0.02% 268
2022
Q1 		– Sell
-946
Closed -$204K – 385
2021
Q4 		$204K Buy
+946
New +$186K 0.01% 328
2017
Q2 		– Sell
-37,801
Closed -$5.12M – 210
2017
Q1 		$5.12M Buy
37,801
+502
+1% +$76K 0.54% 83
2016
Q4 		$5.35M Sell
37,299
-419
-1% -$53.5K 0.58% 72
2016
Q3 		$4.45M Buy
+37,718
New +$4.53M 0.49% 108
2014
Q3 		– Sell
-57,557
Closed -$5.09M – 218
2014
Q2 		$5.09M Buy
57,557
+872
+2% +$83.9K 0.55% 73
2014
Q1 		$5.33M Buy
56,685
+815
+1% +$83.4K 0.64% 56
2013
Q4 		$6.32M Sell
55,870
-2,428
-4% -$219K 0.78% 27
2013
Q3 		$4.6M Buy
58,298
+1,845
+3% +$135K 0.6% 68
2013
Q2 		$3.72M Buy
+56,453
New +$3.64M 0.53% 87

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return

Meritage Portfolio Management's UTHR Position: Q4 2025 in Review

Meritage Portfolio Management reduced its United Therapeutics (UTHR) stake by 18% in Q4 2025, selling an estimated $80.1K and leaving 769 shares worth $375K. The position accounts for 0.02% of the portfolio, ranked #251.

Meritage Portfolio Management first reported a position in UTHR in Q2 2013 and has held it in 24 quarters since. The position peaked at $6.32M in Q4 2013. 838 funds tracked by Wall St. Rank hold UTHR as of Q4 2025.

  • Meritage Portfolio Management held 769 shares of United Therapeutics worth $375K as of Q4 2025.
  • Meritage Portfolio Management sold 172 United Therapeutics shares in Q4 2025, an estimated $80.1K.
  • United Therapeutics made up 0.02% of Meritage Portfolio Management's portfolio in Q4 2025, its #251 holding.
  • Meritage Portfolio Management first reported a position in United Therapeutics in Q2 2013 and has held it in 24 quarters since.
  • Meritage Portfolio Management's United Therapeutics position peaked at $6.32M in Q4 2013.
  • 838 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2025.

Based on Meritage Portfolio Management's 13F filing for Q4 2025, filed 27 Jan 2026.